ID   RBE
AC   CVCL_4896
DR   CLO; CLO_0050848
DR   BioSample; SAMN03472125
DR   cancercelllines; CVCL_4896
DR   CCRID; 1101HUM-PUMC000675
DR   CCRID; 3101HUMTCHu179
DR   Cell_Model_Passport; SIDM01850
DR   CLS; 305019
DR   Cosmic; 1187341
DR   Cosmic; 1571785
DR   Cosmic; 2629289
DR   DepMap; ACH-001856
DR   KCB; KCB 2014049YJ
DR   RCB; RCB1292
DR   Wikidata; Q54949330
RX   CelloPub=CLPUB00275;
RX   PubMed=9358283;
RX   PubMed=15767549;
RX   PubMed=27231123;
RX   PubMed=31077409;
RX   PubMed=35640676;
WW   https://cell.brc.riken.jp/en/rcb/rbessp-25_announce
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JFCR45 cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: 45 hours (PubMed=9358283).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Ser (c.394C>A); ClinVar=VCV000375893; Zygosity=Unspecified (PubMed=27231123; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Misspelling: RBA; CelloPub=CLPUB00275.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): CCRID; DepMap; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9
ST   D16S539: 10,11
ST   D18S51: 13,15
ST   D19S433: 14,15.2
ST   D21S11: 29
ST   D2S1338: 17,24
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 19,24
ST   Penta D: 12
ST   Penta E: 18
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 20
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=9358283; DOI=10.1007/s11626-997-0125-z;
RA   Enjoji M., Sakai H., Nawata H., Kajiyama K., Tsuneyoshi M.;
RT   "Sarcomatous and adenocarcinoma cell lines from the same nodule of
RT   cholangiocarcinoma.";
RL   In Vitro Cell. Dev. Biol. Anim. 33:681-683(1997).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   El-Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//